1-cyclohexylbiduanude | 15233-32-6

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 1-cyclohexylbiduanude
• 英文别名: 1-cyclohexylbiguanide；1-cyclohexyl-biguanide；1-Cyclohexyl-biguanid；N¹-Cyclohexyl-biguanid；Cyclohexyl-biguanid；2-cyclohexyl-1-(diaminomethylidene)guanidine
• CAS: 15233-32-6
• 化学式: C₈H₁₇N₅
• 分子量: 183.256
• InChiKey: USGCMNLQYSXCDU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  103
• 氢给体数：
  3
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-cyclohexylbiduanude 生成 2-氨基-4-环己基氨基-1,3,5-三嗪
  参考文献：
  名称：

  Guanamine Diuretics

  摘要：

  DOI：

  10.1021/ja01575a064
• 作为产物：
  描述：

  环己胺 、 二聚氰胺 在 盐酸 作用下， 以 乙腈 为溶剂， 生成 1-cyclohexylbiduanude
  参考文献：
  名称：

  PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING IMMUNE DISEASES OR INFLAMMATORY DISEASES, CONTAINING BIGUANIDE DERIVATIVE COMPOUND AS ACTIVE INGREDIENT

  摘要：

  本发明涉及一种大叶腺苷衍生物化合物，能够有效预防和治疗免疫性疾病。根据本发明的大叶腺苷衍生物化合物抑制了炎性细胞因子IL-17和TNF-α的产生，增加了具有免疫调节功能的调节性T细胞的活性，并在动物模型中展现出优秀的治疗效果。因此，这种基于大叶腺苷衍生物的化合物可以用作免疫抑制剂或药物组合物，能够预防或治疗由免疫反应失调引起的各种免疫性疾病，如自身免疫性疾病、炎症性疾病和移植排斥等。

  公开号：

  US20170333370A1

文献信息

• THERAPEUTIC COMPOUNDS AND METHODS
  申请人：Regents of the University of Minnesota

  公开号：US20150342909A1

  公开（公告）日：2015-12-03

  Biguanide compounds and salts thereof are disclosed. Also disclosed are pharmaceutical compositions and therapeutic methods for treating certain diseases including cancer such as breast cancer.

  抗酸化剂化合物及其盐已被披露。同时还披露了用于治疗某些疾病的药物组合物和治疗方法，包括乳腺癌等癌症。
• USE OF CYP EXPRESSION TO DIRECT THERAPEUTIC INTERVENTION IN CANCER
  申请人：REGENTS OF THE UNIVERSITY OF MINNESOTA

  公开号：US20180177749A1

  公开（公告）日：2018-06-28

  Certain embodiments of the invention provide a method for identifying a cancer cell that is sensitive to a biguanide compound or other CYP epoxygenase inhibitor, comprising detecting increased expression of at least one cytochrome P450 (CYP) and/or decreased expression of soluble epoxide hydrolase (EPHX2) in the cancer cell, wherein increased CYP expression and/or decreased expression of EPHX2 in the cancer cell correlates with increased sensitivity of the cancer cell to the biguanide compound or other CYP epoxygenase inhibitor.

  本发明的某些实施例提供了一种用于识别对双胍类化合物或其他CYP环氧化酶抑制剂敏感的癌细胞的方法，包括检测癌细胞中至少一个细胞色素P450（CYP）的表达增加和/或可溶性环氧化物水解酶（EPHX2）的表达减少，其中癌细胞中CYP表达增加和/或EPHX2表达减少与癌细胞对双胍类化合物或其他CYP环氧化酶抑制剂的敏感性增加相关。
• THE REACTION OF ACETIC AND TRIFLUOROACETIC ANHYDRIDES WITH SOME SUBSTITUTED GUANIDINE HYDROCHLORIDES
  作者：W. F. Cockburn、R. A. B. Bannard

  DOI：10.1139/v57-171

  日期：1957.11.1

  Acetylation of the hydrochlorides of guanidine, cyclohexylguanidine, and 1-guanylpiperidine has been found to yield substituted triazines. Trifluoroacetylation of 1-guanylpiperidine hydrochloride also gives a triazine, whereas guanidine hydrochloride and cyclohexylguanidine hydrochloride are converted to bistrifluoroacetyl derivatives. The same triazines can also be obtained by acylation of the appropriate

  已经发现胍、环己基胍和1-胍基哌啶的盐酸盐的乙酰化产生取代的三嗪。1-胍基哌啶盐酸盐的三氟乙酰化也产生三嗪，而胍盐酸盐和环己基胍盐酸盐转化为双三氟乙酰基衍生物。同样的三嗪也可以通过适当的双胍酰化得到。
• ACTIVE ESTER COMPOUND AND COMPOSITION AND CURED PRODUCT OBTAINED USING THE SAME
  申请人：DIC Corporation

  公开号：US20200207700A1

  公开（公告）日：2020-07-02

  The present invention aims to provide a means by which a cured product to be obtained has a low dielectric loss tangent and higher heat resistance. Specifically, provided are an active ester compound represented by chemical formula (1): (where in chemical formula (1), Ar 1 is a substituted or unsubstituted first aromatic ring group, and each Ar 2 is independently a substituted or unsubstituted second aromatic ring group, in which at least one of Ar 1 and Ar 2 has an unsaturated bond-containing substituent, and n is an integer of 2 or 3), a curable composition containing the active ester compound, and a cured product thereof.

  本发明旨在提供一种手段，通过该手段可以获得具有低介电损耗正切和更高耐热性的固化产品。具体地，提供了一种由化学式（1）表示的活性酯化合物：（其中，在化学式（1）中，Ar1是取代或未取代的第一芳香环基团，每个Ar2独立地是取代或未取代的第二芳香环基团，其中至少一个Ar1和Ar2具有含有不饱和键的取代基，n是2或3的整数），以及包含活性酯化合物的可固化组合物和其固化产物。
• CURABLE-ON-DEMAND COMPOSITION COMPRISING DUAL REACTIVE SILANE FUNCTIONALITY
  申请人：Yang Yu

  公开号：US20130178553A1

  公开（公告）日：2013-07-11

  A curable composition comprises (a) at least one inorganic or organic compound comprising reactive silane functionality comprising at least one hydrosilyl moiety; (b) at least one inorganic or organic compound comprising reactive silane functionality comprising at least one hydroxysilyl moiety, the hydroxysilyl moiety optionally being generated in situ by hydrolysis of at least one hydrosilyl moiety; and (c) at least one photoactivatable composition that, upon exposure to radiation, generates at least one base selected from amidines, guanidines, phosphazenes, proazaphosphatranes, and combinations thereof; with the proviso that, when component (a) is an organic polymer, then component (b) is different from component (a) and is not generated in situ by hydrolysis of component (a).

  一种可治愈的组合物包括：（a）至少一种含有反应性硅烷官能团的无机或有机化合物，其中硅烷官能团包括至少一个氢硅烷基；（b）至少一种含有反应性硅烷官能团的无机或有机化合物，其中硅烷官能团包括至少一个羟基硅烷基，羟基硅烷基可以通过至少一个氢硅烷基的水解而在原位生成；以及（c）至少一种光活性组合物，当暴露于辐射下时，生成至少一种从氨基甲酸酰胺、鸟嘌呤、磷氮烷、丙氨酸磷酸酯和其组合物中选择的碱，前提是当组分（a）是有机聚合物时，组分（b）与组分（a）不同，并且不是通过组分（a）的水解在原位生成的。